Description: BELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.
Home Page: www.bellushealth.com
BLU Technical Analysis
275 Armand-Frappier Boulevard
Laval,
QC
H7V 4A7
Canada
Phone:
450 680 4500
Officers
| Name | Title |
|---|---|
| Mr. Roberto Francesco Bellini | Pres, CEO & Director |
| Mr. Ramzi Benamar | Chief Financial Officer |
| Dr. Denis Garceau | Chief Scientific Officer |
| Mr. Tony Matzouranis | Sr. VP of Bus. Devel. |
| Dr. Catherine M. Bonuccelli M.D. | Chief Medical Officer |
| Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBA | Chief Operating Officer |
| Mr. Daniel Matthews | Director of Investor Relations & Communications |
| Mr. Francois Desjardins C.A., CPA, CPA, CA | Sr. VP of Fin. |
| Mr. Sebastien Roy | Corp. Sec. |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0459 |
| Price-to-Sales TTM: | 104093.7 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |